Healthy Q2 and H1; resulting in consecutive guidance upgrade
04/08/22 -"DiaSorin released healthy Q2 results. While, as expected, non-COVID-19 offerings continued to do well, slower-than-expected moderation in COVID-19 testing sales was a pleasant surprise – also ..."
Pages
66
Language
English
Published on
04/08/22
You may also be interested by these reports :
01/09/26
We have resumed our coverage of the Tecan Group, updating the company’s accounts and our forecasts. The share price has gained strong momentum since ...
01/09/26
Dräger’s final Q2 26 results confirmed margin acceleration across both divisions, alongside a sharp improvement in FCF and net debt. The key ...
27/08/26
Elekta’s Q1 sales fell short of expectations, although profitability surpassed forecasts. The top line declined due to underperformance in Solutions, ...
27/08/26
EssilorLuxottica (EL) (BUY; France) share price peaked in late 2026 and has shed 40% ytd. No small feat for a stock that used to be worth more than ...